References
- Omoto E, Deguchi S, Takaba S, et al. Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. Leukemia 1996;10:609–614.
- Denzlinger C, Bowen D, Benz D, et al. Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia. Br J Haematol 2000;108:93–95.
- Robak T, Szmigielska-Kapłon A, Urbanska-Rys H, et al. Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. Neoplasma 2003;50:172–175.
- Anargyrou K, Vaiopoulos G, Terpos E, et al. Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia. Haematologia (Budap) 2002;32:169–173.
- Greenberg PL, Cox C, Le Beau MM, et al. International scoring system for prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2089.
- Visani G, Malagola M, Piccaluga PP, Isidor A. Low dose Ara-C for myelodysplastic syndromes: is it still a current therapyLeuk Lymphoma 2004;45:1531–1538.
- Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419–425.